达沙替尼产生长期缓解外骨髓性白血病:一个回顾性观察性研究
I Cunningham1, R A Fisher2, J Yang2
1Division of Hematology Oncology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
European journal of haematology
|December 10, 2025
概括
达沙替尼在治疗外骨髓性白血病 (EML) 中表现有前途,大多数患者实现了缓解. 这种向治疗为EML患者的长期无病生存提供了希望.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 从历史上看,外骨髓性白血病 (EML) 缺乏有效的治疗方法.
- 意马替尼抗性需要使用替代治疗策略.
- 达沙替尼,一种双重BCR::ABL1/SRC抑制剂,已成为一种潜在的治疗选择.
研究的目的:
- 为了评估达萨提尼布在患有异常白血病 (EML) 的患者中的疗效.
- 评估用达沙替尼布治疗EML患者的缓解持续时间和长期结果.
- 探索达沙替尼在EML中的潜在作用机制.
主要方法:
- 对163名EML患者进行了回顾性观察性研究,这些患者接受了达沙替尼 ± 传统疗法治疗.
- 数据收集包括缓解持续时间,反应记录 (MRI,CSF,PET/CT,尸检) 和随后的治疗 (移植,CAR-T疗法).
- 在EML组织中分析氨酸激酶表达,以确定潜在的标.
主要成果:
- 在163名患者中,有157名患者 (96%) 实现了EML参与的缓解.
- 缓解持续时间从2年到超过11年,其中15次缓解超过4年.
- 达萨提尼布准的SRC激酶LCK被确定为EML的潜在组织标.
结论:
- 达沙替尼 (Dasatinib) 显示出在实现长期缓解外骨髓性白血病 (EML) 中具有显著的疗效.
- 这些发现表明达沙替尼是潜在的改变EML实践的向治疗.
- 需要进一步的前性试验来验证达沙替尼的成功,并确定其与其他疗法并行的作用.
相关概念视频
01:22Connective Tissue Cell Types
Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...